 |
|
The P-450 SystemDefinition and Relevance to the Use of Antidepressants in Medical Practice
Richard J. Goldberg, MD
Arch Fam Med. 1996;5(7):406-412.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. Wrighton S, Stevens J. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22:1-21.
PUBMED
2. Guengerich F. Human cytochrome P-450 enzymes. Life Sci. 1992;50:1471-1478.
PUBMED
3. Nebert D, Nelson D, Adesnik M. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA Seq. 1989;8:1-13.
4. Nelson D, Kamataki T, Wasman D. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1-51.
PUBMED
5. Murray M, Reidy G. Selectivity in the inhibition of mammalian cytochromes P450 by chemical agents. Pharmacol Rev. 1990;42:85-101.
PUBMED
6. Lledo P, Abrams S, Johnson A. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur J Clin Pharmacol. 1993;44:63-67.
PUBMED
7. Nakamura K, Goto F, Ray W, McAllister C, Jacqz E, Wilkinson G. Interethnic difference in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985;38:402-408.
PUBMED
8. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet. 1990;18:220-239.
PUBMED
9. Wedlund P, Aslanian W, McAllister C, Wilkinson G, Branch R. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984;36:773-780.
PUBMED
10. Butler M, Lang N, Young J, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-127.
PUBMED
11. Sanz E, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther. 1989;45:495-499.
PUBMED
12. Preskorn S. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med. 1993;94(suppl_5A):2S-12S.
PUBMED
13. Tsujimoto G, Hashimoto K, Hoffman B. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age: part 2. Int J Clin Pharmacol Ther Toxicol. 1989;27:102-116.
PUBMED
14. Hunt C, Westerkam W, Stave G, Wilson G. Hepatic cytochrome P-4503A activity in the elderly. Mech Ageing Dev. 1992;64:189-199.
PUBMED
15. Pollock B, Perel J, Kirshner M, Altieri L, Yeager A, Reynolds C. Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol. 1991;40:609-611.
PUBMED
16. Pollock BG, Perel JM, Altieri L, Kirshner M, Yeager A, Reynolds C. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull. 1992;28:163-168.
PUBMED
17. Brosen K, Skejlbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6: the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol. 1991;32:136-137.
PUBMED
18. Crewe H, Lennard M, Tucker G. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYPD6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262-265.
PUBMED
19. von Moltke L, Greenblatt D, Court M. Inhibition of aprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
PUBMED
20. Otton S, Crewe H, Lennard M, Tucker G, Woods H. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther. 1988;247:242-247.
FREE FULL TEXT
21. Ujhelyi M, O'Rangers E, Fan C, Kluger J, Pharand C, Chow M. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. Clin Pharmacol Ther. 1993;53:38-48.
PUBMED
22. Greene D, Dockens R, Salazar D. Coadministration of nefazodone and benzodiazepines, I: pharmacokinetic assessment. Clin Pharmacol Ther. 1994;55:141. Abstract.
23. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and humans. Int J Clin Pharmacol Res. 1983;111:449-458.
24. Honig P, Wortham D, Zamani K, Cantilena L. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 1994;7:148-156.
25. Knodell R, Holtzman J, Crankshaw D, Steele N, Stanley L. Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology. 1982;82:84-88.
PUBMED
26. Honig P, Wortham D, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
FREE FULL TEXT
27. Crane J, Shih H-T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med. 1993;95:445-446.
PUBMED
28. Canafax D, Graves N, Hilligoes D. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation. 1991;51:1014-1018.
PUBMED
29. Joblin M. Possible interaction of sertraline with carbamazepine. N Z Med J. 1994;107:43.
PUBMED
30. Greenblatt D, Preskorn S, Cotreau M, Horst W, Harunatz J. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486.
PUBMED
31. Lemberger L, Rowe H, Bosomworth J, Tenbarge J, Bergstrom R. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988;43:412-419.
PUBMED
32. Lasher T, Fleishaker J, Steenwyck R, Antal E. Pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl). 1991;104:323-327.
PUBMED
33. Grimsley S, Jann M, Carter J. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50:10-15.
PUBMED
34. Swims M. Potential terfenadine-fluoxetine interaction. Ann Pharmacother. 1993;27:1404-1405.
PUBMED
35. Brosen K, Skjelbo E, Rasmussen B. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214.
PUBMED
36. Fuhr U, Anders E, Mahr G. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992;36:942-948.
FREE FULL TEXT
37. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry. 1992;55:412-413.
FREE FULL TEXT
38. Woods DJ, Coulter DM, Pilands P. Interaction of phenytoin and fluoxetine. N Z Med J. 1994;107:19.
PUBMED
39. Nightingale S. Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. JAMA. 1994;271:1067.
FREE FULL TEXT
40. Skejelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992;34:256-261.
PUBMED
41. Bloomer J, Woods F, Haddock R. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;25:521-523.
42. Otton S. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther. 1993;53:401-409.
PUBMED
43. Preskorn S. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34.
44. Bell I, Cole J. Fluoxetine induced elevation of desipramine levels and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol. 1988;8:447-448.
PUBMED
45. Lydiard R, Anton R, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry. 1993;150:1125-1126.
PUBMED
46. Vandel S, Bertschy G, Bonin B. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology. 1992;25:202-207.
PUBMED
47. Klamerus K, Maloney K, Rudolph R, Sisenwine S, Jusko W, Chiang S. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724.
ABSTRACT
48. Rosenblatt J, Rosenblatt N. More about spontaneous post marketing reports of bupropion-related seizures. Curr Affect Illness. 1992;11:18-20.
49. Goff D, Midha K, Brotman A. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry. 1991;148:790-792.
FREE FULL TEXT
50. Llerena A, Alm C, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14:92-97.
PUBMED
51. Malek-Ahmadi P, Allen S. Paroxetine-molindone interaction. J Clin Psychiatry. 1995;56:82-83.
PUBMED
52. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.
PUBMED
53. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenboughs R, Heykants J. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos. 1993;21:1134-1141.
ABSTRACT
54. Fisher V, Vogels B, Maurer G, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal cytochrome P450 2D6. J Pharmacol Exp Ther. 1992;260:1355-1360.
FREE FULL TEXT
55. Funck-Brentano C, Thomas G, Jacqa-Aigrain E. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther. 1992;263:780.
FREE FULL TEXT
56. Lee J, Kroemer H, Silberstein D, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990;322:1764-1768.
ABSTRACT
57. Lennard M, Silas J, Freestone S, et al. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-1560.
PUBMED
58. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun. 1988;152:411-416.
PUBMED
59. Sindrup S, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990;48:686-693.
PUBMED
60. Hansen T. Interaction of fluoxetine and pentazocine. Am J Psychiatry. 1990;147:949-950.
FREE FULL TEXT
61. Schadel M, Wu D, Otton S, Kalow W, Sellers E. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15:263-269.
PUBMED
62. Kivisto K, Neuvonen P, Klotz U. Inhibition of terfenadine metabolism. Clin Pharmacokinet. 1994;27:1-5.
PUBMED
63. von Moltke L, Greenblatt DJ, Cotreau-Bibbo M, Duan S, Hamartz J, Shader R. Inhibition of desipramine hydoxylation in vitro by serotoninreuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Pharmacol Exp Ther. 1994;268:1278-1283.
FREE FULL TEXT
64. Propulsid [product insert]. Titusville, NJ: Janssen Pharmaceutica Inc; 1995. 65. Lemoine A, Gauthier J, Azoulay D. Major pathway of imipramine metabolism is catalyzed by cytochromes P4501A2 and P4503A4 in human liver. Mol Pharmacol. 1993;43:827-832.
ABSTRACT
66. Guengerich F, Martin M, Beaune P. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation: a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986;261:5051-5060.
FREE FULL TEXT
67. Prichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochrome P-450 IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711-719.
ABSTRACT
68. von Moltke L, Greenblatt D, Harmatz J, Shader R. Cytochromes in psychopharmacology. J Clin Psychopharmacol. 1994;14:1-4.
PUBMED
69. Mani C, Pearce R, Parkinson A. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 1994;15:2716-2720.
70. Kerr B, Thummel K, Wurden C. Human liver carbamazepine metabolism: roles of CYP3A4 and CYP2C8 in 10, 11 epoxide formation. Biochem Pharmacol. 1994;47:1968-1979.
71. Henricsson S, Lindholm A, Aravogolou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol. 1990;66:49-52.
PUBMED
72. Waxman D, Attisano C, Guengerich F, Lapenson D. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6B-hydoxylase cytochrome P450 enzyme. Arch Biochem Biophys. 1988;263:424-436.
PUBMED
73. Pollak B. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994;2:204-213.
PUBMED
74. von Moltke L, Greenblatt D, Harmatz J, Shader R. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology. 1993;47:268-276.
PUBMED
75. Kronbach T, Mathys D, Umeno M. Oxidation of midazolam and triazolam by human cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89-96.
ABSTRACT
76. Varhe A, Olkkola K, Neuvonen P. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56:601-607.
PUBMED
77. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther. 1994;56:471-476.
PUBMED
78. Fleishaker J, Hulst L. Effect of fluvoxamine on the pharmacokinetics and phrmacodynamics of alprazolam in healthy volunteers. Pharm Res. 1992;9(suppl):S292.
79. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 1994;14:279-281.
PUBMED
80. Daniel D, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol. 1994;14:340-343.
PUBMED
81. Cognex [product monograph]. Morris Plains, NJ: Parke-Davis; 1993. 82. Sesardic D, Boobis A, Edwards R. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-demethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol. 1988;26:363-372.
PUBMED
83. Campbell M, Grant D, Inaba T. Biotrasformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome P450 in human liver microsomes. Drug Metab Dispos. 1987;15:237-248.
ABSTRACT
84. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32:313-334.
PUBMED
85. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinetics. 1993;24:203-220.
PUBMED
86. Bertschy G. Probable metabolic interaction between methadone and fluvoxamine in addicted patients. Ther Drug Monit. 1994;16:42-45.
PUBMED
87. DeVane L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55:38-45.
PUBMED
88. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYPsC19 is the major (s)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994;33:1743-1752.
PUBMED
89. Bertilsson L, Hentorn T, Sanz E, Tybring G, Säwe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-355.
PUBMED
90. Abernethy D, Greenblatt D, Shader R. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther. 1985;232:183-188.
FREE FULL TEXT
91. Ward SA, Walle T, Walle U, Wilkinson GR, Branch R. Propranolol's metabolism is determined by both mephytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther. 1989;45:72-79.
PUBMED
92. Knodell RG, Hall SD, Wilkinson GR, Guengerich F. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther. 1987;241:1112-1119.
FREE FULL TEXT
93. Smith D, Jones B. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol. 1992;44:2089-2098.
PUBMED
94. Maurer PM, Bartkowski RB. Drug interactions of clinical significance with opioid analgesics. Drug Saf. 1993;8:30-48.
PUBMED
95. Woolsey R, Chen Y, Freiman J, Gillis RA. Mechanism of the cardiotoxic action of terfenadine. JAMA. 1993;269:1532-1539.
FREE FULL TEXT
96. Monahan B, Ferguson C, Killeavy E. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
FREE FULL TEXT
97. Drake W, Gordon G. Heart block in a patient on propranolol and fluoxetine. Lancet. 1994;343:425-426.
PUBMED
98. Walley T, Pirmohamed M, Proudlove C, Max-well D. Interaction of metoprolol and fluoxetine. Lancet. 1993;341:967-968.
PUBMED
99. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-depressed cytochrome P-450: a role for P4502C9 in the etiology of (s)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59.
PUBMED
100. Grasela T, Antal E, Ereshefsky L. An evaluation of population pharmacokinetics in therapeutic trials, II: detection of a drug-drug interaction. Clin Pharmacol Ther. 1987;42:433-441.
PUBMED
101. Preskorn S, Alderman J, Chung M. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98.
PUBMED
102. Kurtz D, Bergstrom R, Goldberg M, Cerimale B. Drug interaction between sertraline and desipramine or imipramine. J Clin Pharmacol. 1994;34:1009-1033. Abstract.
103. Rapeport W, Williams S, Muirhead D, Dewland P, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry. 1996;57(suppl 1):20-23.
PUBMED
104. Rapeport W, Muirhead D, Williams S, Cross M, Wesnes K. Absence of effect of sertraline on the phamacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry. 1996;57(suppl 1):24-28.
|
